21.09.2015 13:20:54

Sangamo Reports Updated Clinical Data From ZFP Therapeutic Program For HIV

(RTTNews) - Sangamo BioSciences, Inc. (SGMO) presented data demonstrating sustained functional control of viral load in the absence of antiretroviral drugs in two of three HIV-infected subjects treated in Cohort 3 of its Phase 1/2, or SB-728-1101, study of its ZFP Therapeutic, or SB-728-T, for the treatment of HIV/AIDS.

The company's scientists reported on the progress of two of three subjects in Cohort 3, who had received an SB-728 product that included CCR5 modified CD8 T-cells. These patients' regimen differed from subjects treated in other cohorts in the 1101 study, who had received only CCR5-modified CD4 T-cells after Cytoxan preconditioning. The Cohort 3 treatment regimen was designed to test whether inclusion of CCR5-modified CD8 T-cells, the immune cells responsible for controlling viral infections, could improve HIV viral load control.

"The ability of subjects treated in Cohort 3 to suppress and sustain control of viral load, combined with durable increases in CD4 and CD8 cells, provide support for our hypothesis of an immunologic mechanism of action for SB-728," said Dale Ando, Sangamo's vice president of therapeutic development and chief medical officer.

Analysen zu Sangamo Therapeutics Incmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Sangamo Therapeutics Inc 2,60 2,76% Sangamo Therapeutics Inc